Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis

This meta-analysis was performed to determine the optimal use of anti-EGFR mAb in the treatment of metastasized colorectal cancer (mCRC). Seventeen randomized clinical trials were included, all evaluating the added value of anti-EGFR mAb to standard treatment line in patients with KRAS wild-type mCR...

Descripción completa

Detalles Bibliográficos
Autores principales: van Helden, E. J., Menke-van der Houven van Oordt, C. W., Heymans, M. W., Ket, J. C. F., van den Oord, R., Verheul, H. M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557867/
https://www.ncbi.nlm.nih.gov/pubmed/28695301
http://dx.doi.org/10.1007/s10555-017-9668-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557867/
https://www.ncbi.nlm.nih.gov/pubmed/28695301
http://dx.doi.org/10.1007/s10555-017-9668-y

Ejemplares similares